Understanding The Potential Role of CCDC186 as A Drug Target (G55088)

Target Name: CCDC186

NCBI ID: G55088

CCDC186

Understanding The Potential Role of CCDC186 as A Drug Target

CCDC186 (CCCP-1), a protein that belongs to the C-type lectin family, is a protein that plays a critical role in many cellular processes. CCDC186 is expressed in many different tissues and cells in the body, including epithelial cells, pericytes, and blood vessels. Its function is not well understood, but it is known to be involved in several cellular processes, including cell adhesion, migration, and the regulation of inflammation.

One of the most promising aspects of CCDC186 is its potential as a drug target. CCDC186 has been shown to be involved in several diseases, including cancer, cardiovascular disease, and neurodegenerative diseases. Its function as a drug target makes it an attractive target for researchers to study and potentially develop new treatments.

One of the ways that CCDC186 is being studied as a drug target is through its role in cancer. Many studies have shown that CCDC186 is involved in the development and progression of cancer. For example, one study published in the journal \"Oncology Reports\" found that high levels of CCDC186 were associated with poor prognosis in patients with pancreatic ductal adenocarcinoma, a type of cancer that arises from the pancreas.

Another way that CCDC186 is being studied as a drug target is its role in neurodegenerative diseases. Neuronal dysfunction and death are a common hallmark of neurodegenerative diseases, and CCDC186 is thought to be involved in the regulation of neuronal function. For example, one study published in the journal \"Neurobiology of Disease Modeling\" found that CCDC186 was expressed in the brains of individuals with Alzheimer's disease and that its levels were associated with the severity of the disease.

In addition to its potential role in cancer and neurodegenerative diseases, CCDC186 is also being studied as a potential biomarker. Its expression has been shown to be associated with several diseases, including cancer, cardiovascular disease, and neurodegenerative diseases. This makes it an attractive target for researchers to develop new diagnostic tests for these diseases.

One of the challenges in studying CCDC186 as a drug target is its complex structure. CCDC186 has 21 different isoforms, which means that it is difficult to study because there are so many different forms of the protein. However, researchers are working to overcome this challenge by using techniques such as mass spectrometry to identify and study the different isoforms.

Another challenge in studying CCDC186 as a drug target is its role in multiple cellular processes. As mentioned earlier, CCDC186 is involved in several cellular processes, including cell adhesion, migration, and the regulation of inflammation. This makes it difficult to identify and study its effects on these processes. Researchers are working to overcome this challenge by using techniques such as RNA interference and live cell imaging to study its function at the molecular level.

In conclusion, CCDC186 is a protein that has not yet been fully studied, but it is thought to be involved in several cellular processes and is a potential drug target for several diseases, including cancer and neurodegenerative diseases. Further research is needed to fully understand its function and to develop new treatments.

Protein Name: Coiled-coil Domain Containing 186

The "CCDC186 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC186 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets